RTCT raises hard questions about sponsor liability, blinding integrity, DSMB overlap, and AI accountability that the industry hasn’t yet resolved. Both sides of that ledger deserve honest consideration.
- Pharma's Digital Transformation: Where It's Really At
- How AI Is Changing Clinical Trial Design, Not Just Speed
- What Is Clinical Trials Day? Why Technology Helps Research Rise
- DiMe's Navigator: Why Teams Still Stall On Digital Endpoints
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- Digital Endpoints Are Ready. Clinical Development Isn't
- Why Clinical Trial Data Cleaning Must Go Continuous (And How To Do It)
- What Clinical Analytics Solutions Are Shaping Clinical Research
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Oncology Preferences From Patients And Caregivers On Trial Tech
Delve into the preferences of patients and caregivers in the field of oncology, specifically regarding eConsent, telehealth, wearables, and other digital technologies.
-
EDC Selected To Support Biotech Advances In Diabetes
Find out why one leading biotechnology company keeps choosing this eClinical technologies and services provider for EDC assistance.
-
Statistics & Data Management Group Reaches New Heights Of Clinical Trial Efficiency
Explore how a contract research organization was able to migrate from paper-based processes to cost-effectively increase efficiency, safeguard data quality, and deliver exceptional service levels to sponsors.
-
Top HEOR Trends
Real-world evidence (RWE) offers insights into the effectiveness of medical treatments in everyday settings, with various stakeholders utilize RWE to enhance healthcare.
-
Outlook For 2025: New Forces Driving Pragmatic Innovation
Clinical data trends are evolving rapidly to reduce trial complexity, improve patient experiences, and shorten development timelines.
-
EDC System Provides Flexibility, Scalability For Mid-Study Changes
Discover the importance of using a robust, scalable, and flexible EDC solution that handles mid-study changes for even the most complex clinical trials.
-
Build Or Buy: Adopting AI Agents In Life Sciences
Should your team build custom AI agents from scratch or partner with a ready-made solution? This practical guide cuts through the hype to reveal the strategic insights you need.
-
7 eCOA Design Recommendations: Insights From Sites And CRAs
Signant joined a group of C-Path members including other eCOA solution providers, sponsors, and regulators for a GBTI project that revealed several opportunities to improve eCOA usability and flexibility.
-
8 Key Applications Of Real-World Data In Multiple Myeloma Therapy Development
Explore how therapeutic area (TA) datasets can be leveraged to address the challenges multiple myeloma (MM) presents in the field of hematologic malignancies.
-
Why Oncology Drug Development Lags In Digital Biomarkers
Despite technological advances, oncology drug development research has lagged in adopting wearable digital biomarkers. Explore this space's unique challenges and the benefits of wearable technology.
RECENT NEWSLETTERS
- 06.06.26 -- Best Of May: AI Risk, CRO Strategy, And Trial Cost Control
- 06.04.26 -- Why Clinical Execution — Not Tech — Is Trials' Biggest Risk
- 05.28.26 -- FDA's Elsa AI Shift, RTCT Rules, And RWE That Works
- 05.21.26 -- AI, HEOR, And Hidden Costs Reshaping Clinical Trials
- 05.14.26 -- AI, RWE, And The Systems Breaking Clinical Trials